A robust new clinical trial has shown that Fresh Olive Leaf Extract has significant effects on insulin in men who are at risk of developing type II diabetes. The randomised cross-over double blind controlled clinical trial reveals olive leaf extract offers significant improvement in the action of insulin and the way it is secreted in overweight men. Type II diabetes is highest in overweight or obese people and occurs as a result of insulin not working effectively in the body. The findings, published in an international journal, could help the UK’s ageing and increasingly overweight population or “dia-risk” to help prevent onset of the disease.
The clinical trial was conducted at the Liggin’s Institute, based at The University of Auckland in New Zealand. The scientists monitored 47 overweight males who were at risk of developing type II diabetes. The study used Comvita’s Fresh Olive Leaf Extract, a black liquid which is made from the resilient, bitter-tasting leaves of the olive tree. The trial revealed that a 12 week course of the natural supplement improved insulin action to healthier levels. On average a 28% improvement in insulin secretion and a 15% improvement in insulin action was witnessed in the olive leaf group when compared to placebo.
The research suggests that a daily tablespoon of fresh olive leaf extract (or two capsules) holds promise for the millions of “Dia-risk” individuals in the UK as part of a preventative strategy against the onset of Type II diabetes. A condition which recent research suggests costs the NHS nearly £10 billion.
Around 1 in 20 people in the UK are Type II diabetics and it is most likely to affect those with a BMI >30, although ethnicity also plays a part. It is also estimated that around 2% of people in the UK have type II diabetes, but are undiagnosed. Further millions of British adults and increasingly teenagers are “dia-risk”, meaning they are likely to develop the condition: such as those with an overweight or obese BMI, older people or those with a genetic predisposition.
Insulin is an essential tool in the body; it allows glucose to pass into the cells of the body to be used as energy. However in Type II diabetes (and to some extent the “dia-risk”) the pancreas cannot produce as much insulin as it needs to or this insulin can no longer be used effectively by the cells (known as insulin resistance). This means the glucose isn’t being used effectively in the body and remains in the blood leading to elevated blood sugar levels.
Diabetes Type II is a serious condition and many UK sufferers rely on prescribed drugs to treat their condition. This is not ideal as many common diabetic medications that are currently prescribed in the UK have been linked to unpleasant side effects such as sickness and diarrhoea – and serious health implications such as increased risk of heart failure.
“We are pleased to report that Olive Leaf was well tolerated by all participants with no major side effects,” Dr Ralf Schlothauer, Chief Technical Officer for Comvita, comments. “The study found on average a 15% improvement in insulin action, a very encouraging result.”
“While we are very excited by the findings of the clinical trial, we would not advise any Type II diabetics to use olive leaf in place of medications prescribed by their doctor,” Simon Pothecary, UK spokesperson for Comvita comments “However the research holds promise for the millions of people who are at risk of developing the disease, perhaps they are overweight or there is a family history of the condition.”
While much research has focused on the health benefits of olive oil, new data regarding olive leaf is emerging. Active compounds found in olive oil called ‘polyphenolics’ have been identified, but the olive leaf contains these in much higher concentrations – around 30-40 times stronger.